Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755422 | 1.00 | KHK (0.69) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL27883168 | 0.84 | KDM4E (0.57) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL566209 | 0.84 | KHK (0.57) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL12682590 | 0.82 | KHK (0.62) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL23860817 | 0.82 | KHK (0.62) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL25216528 | 0.82 | KHK (0.62) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL23860801 | 0.82 | KHK (0.73) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL23860773 | 0.82 | KHK (0.53) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL30377261 | 0.82 | KHK (0.62) | KHKCSNK1A1CLK4ALDH1A1KDM4E | |
| SCHEMBL9967116 | 0.82 | KHK (1.00) | KHKCSNK1A1CLK4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4447962-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023213761-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-11696928-B2 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | UNIVERSITE DE MONTREAL (CA) | 2023-07-11 | — | — | US | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20200323923-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2020-10-15 | — | — | US | disclosed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6610692-B1 | Anticoagulants | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6376499-B1 | PIPERAZINE-AMIDE COMPOUND WITH ANTICOAGULANT ACTIVITY | MERCK & CO., INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124823-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026210-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-4725687-A | ANTITUMOR AGENTS; SIDE EFFECT REDUCTION; POTENCY | SOUTHERN RESEARCH INSTITUTE (US) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | KHK 4005/4885CSNK1A1 963/4885CLK4 4846/4885 |
| US-11696928-B2 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | MCL1, CD47, BMI1 | KHK 4772/4885CSNK1A1 3510/4885CLK4 4634/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | KHK 4089/4885CSNK1A1 833/4885CLK4 4805/4885 |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | KHK 409/4885CSNK1A1 1925/4885CLK4 621/4885 |
| US-20200323923-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | MCL1, CD47, BMI1 | KHK 4772/4885CSNK1A1 3510/4885CLK4 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.